全文获取类型
收费全文 | 70160篇 |
免费 | 7002篇 |
国内免费 | 2704篇 |
专业分类
耳鼻咽喉 | 170篇 |
儿科学 | 745篇 |
妇产科学 | 389篇 |
基础医学 | 3104篇 |
口腔科学 | 485篇 |
临床医学 | 6215篇 |
内科学 | 7857篇 |
皮肤病学 | 1462篇 |
神经病学 | 2419篇 |
特种医学 | 818篇 |
外国民族医学 | 8篇 |
外科学 | 2238篇 |
综合类 | 9048篇 |
现状与发展 | 5篇 |
一般理论 | 3篇 |
预防医学 | 4851篇 |
眼科学 | 685篇 |
药学 | 31611篇 |
76篇 | |
中国医学 | 3435篇 |
肿瘤学 | 4242篇 |
出版年
2024年 | 255篇 |
2023年 | 1289篇 |
2022年 | 2146篇 |
2021年 | 2905篇 |
2020年 | 2886篇 |
2019年 | 2712篇 |
2018年 | 2693篇 |
2017年 | 2913篇 |
2016年 | 2770篇 |
2015年 | 2744篇 |
2014年 | 4813篇 |
2013年 | 7501篇 |
2012年 | 4695篇 |
2011年 | 4766篇 |
2010年 | 3897篇 |
2009年 | 3299篇 |
2008年 | 3091篇 |
2007年 | 3071篇 |
2006年 | 2772篇 |
2005年 | 2469篇 |
2004年 | 2093篇 |
2003年 | 1905篇 |
2002年 | 1440篇 |
2001年 | 1373篇 |
2000年 | 1067篇 |
1999年 | 935篇 |
1998年 | 831篇 |
1997年 | 765篇 |
1996年 | 642篇 |
1995年 | 614篇 |
1994年 | 514篇 |
1993年 | 435篇 |
1992年 | 500篇 |
1991年 | 412篇 |
1990年 | 340篇 |
1989年 | 272篇 |
1988年 | 293篇 |
1987年 | 265篇 |
1986年 | 207篇 |
1985年 | 233篇 |
1984年 | 200篇 |
1983年 | 135篇 |
1982年 | 122篇 |
1981年 | 114篇 |
1980年 | 71篇 |
1979年 | 75篇 |
1978年 | 82篇 |
1977年 | 59篇 |
1976年 | 53篇 |
1975年 | 52篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
欧洲药品局(EMA)于2018年11月发布了"人用药品辅料右旋糖酐的包装说明书资料",该文件引用大量文献全面评价了右旋糖酐的安全性,特别指出含有右旋糖酐辅料的注射和吸入制剂的疫苗与药品,应在说明书中描述有关其过敏反应信息的新要求。介绍该文件的主要内容,期望对我国这类药品说明书的撰写和监管有所帮助。 相似文献
32.
Sania Amr Magdy Garas Dina N. K. Boulos Doa’a A. Saleh Irene A. Jillson Christopher A. Loffredo 《Journal of substance use》2019,24(3):341-345
Background: Egyptian street youth use substances including tobacco, illicit drugs, and pharmaceutical drugs. To understand the circumstances, including adverse childhood experiences, that place adolescents at risk for engaging in substance use, we conducted in-depth interviews among a sample of Egyptian street children. Methods: From youth residing at or attending Caritas, a non-profit organization, which provides shelter and education to street youth, seven girls and twelve boys, aged 12–18 years, participated in open-ended, in-depth interviews. Results: Eight out of the 19 participants reported family history (early exposure) to substance use; and seven of them were initiated by either a family member (sibling), friend or coworker. Most of the participants reported a history of conflict with or abuse (verbal or physical) by their parents or siblings, or stressful situations at home; they used substance(s) to alleviate their stress. Few attended school, and some were forced to work and help their family. Conclusions: Among Egyptian youth, adverse childhood experiences, such as poverty, child abuse, and family substance use, challenge somewhat susceptible youths and lead them to the path of substance use and addiction. Prevention intervention should be multifaceted, culturally adaptable, and primarily targeting the social environment during childhood. 相似文献
33.
Conan MacDougall Theora Canonica Chris Keh Binh An P. Phan Janice Louie 《Pharmacotherapy》2022,42(4):343-361
Rifamycins (rifampin, rifabutin, and rifapentine) play an essential role in the treatment of mycobacterial and some nonmycobacterial infections. They also induce the activity of various drug transporting and metabolizing enzymes, which can impact the concentrations and efficacy of substrates. Many anticoagulant and antiplatelet (AC/AP) agents are substrates of these enzymes and have narrow therapeutic indices, leading to risks of thrombosis or bleeding when coadministered with rifamycins. The objective of this systematic review was to evaluate the effects on AC/AP pharmacokinetics, laboratory markers, and clinical safety and efficacy of combined use with rifamycins. A systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidance was performed. The PubMed, Embase, and Web of Science databases were queried for English-language reports on combination use of rifamycins and AC/AP agents from database inception through August 2021. The 29 studies identified examined warfarin (n = 17), direct oral anticoagulants (DOACs) (n = 8), and antiplatelet agents (n = 4) combined with rifampin (n = 28) or rifabutin (n = 1). Eleven studies were case reports or small case series; 14 reported on pharmacokinetic or laboratory markers in healthy volunteers. Rifampin-warfarin combinations led to reductions in warfarin area under the curve (AUC) of 15%–74%, with variability by warfarin isomer and study. Warfarin dose increases of up to 3–5 times prerifampin doses were required to maintain coagulation parameters in the therapeutic range. DOAC AUCs were decreased by 20%–67%, with variability by individual agent and with rifampin versus rifabutin. The active metabolite of clopidogrel increased substantially with rifampin coadministration, whereas prasugrel was largely unaffected and ticagrelor saw decreases. Our review suggests most combinations of AC/AP agents and rifampin are problematic. Further studies are required to determine whether rifabutin or rifapentine could be safe alternatives for coadministration with AC/AP drugs. 相似文献
34.
35.
BackgroundPercutaneous endoscopic gastrostomy (PEG) is required for Levodopa/Carbidopa Intestinal Gel (LCIG) delivery in patients with advanced Parkinson's disease (PD) as well as for enteral feeding in a variety of neurological disorders. Buried Bumper Syndrome (BBS) is a serious complication of PEG. The frequency of BBS in patients receiving LCIG treatment has never been reported.ObjectivesTo compare the frequency of BBS in patients on LCIG treatment or on enteral feeding over the past 12 years and identify possible risk factors.MethodsWe reviewed prospectively recorded data from 2009 to 2020 on two case-series: LCIG-treated PD patients and non-PD patients on enteral nutrition. We identified all BBS incidences. Patients’ characteristics, clinical manifestations, BBS management, possible risk factors and outcomes were analyzed.ResultsDuring the 12 years, 35 PD patients underwent PEG insertion for LCIG infusion, and 123 non-PD patients for nutritional support. There were eight cases of BBS in six PD patients (17.1%). Six of them were effectively managed without treatment discontinuation. Of the enteral feeding patients, only one developed BBS (0.8%) (p < 0.001). We identified inappropriate PEG site aftercare, weight gain, early onset PD, longer survival, treatment duration, dementia and PEG system design as potential risk factors for BBS development.ConclusionsBBS occurs more frequently in LCIG patients than in patients receiving enteral feeding. If detected early, it can be successfully managed, and serious sequalae or treatment discontinuation can be avoided. Regular endoscopic follow-up visits of LCIG-treated patients and increased awareness in patients and clinicians are recommended. 相似文献
36.
37.
38.
39.
血吸虫病是一种严重危害人类健康、影响社会经济发展的重大传染病,为全球公共卫生负担和危害最严重的被忽视的热带病之一。吡喹酮是20世纪70年代研制出的一种高效、低毒、价廉的广谱抗蠕虫口服药,为世界卫生组织(WHO)推荐的抗血吸虫的首选药物。吡喹酮在血吸虫病流行区现场大规模反复使用已超过40年,血吸虫是否会对吡喹酮产生抗药性引起国际社会极大担忧,为学术界关注的热点科学问题。针对血吸虫病防治中这一重大需求,自1996年起, 在国家科技支撑计划、国家自然科学基金、江苏省自然科学基金等项目基金资助下,我们在血吸虫病流行区现场和实验室,对血吸虫在吡喹酮药物的压力是否会产生抗药性、抗性虫株的生物学特性、抗性的检测、吡喹酮抗性的交叉抗药性及抗药性的预防和控制等科学问题进行较为系统的研究,本文就其研究及其意义作一概述。 相似文献
40.
《Clinical Lymphoma, Myeloma & Leukemia》2022,22(8):608-617
BackgroundConsiderable progress has been made in therapeutic options for multiple myeloma (MM). Understanding the current landscape of MM treatment options and associated outcomes in the real world is important in providing key insights into clinical and knowledge gaps which could be targeted for further optimization.MethodsThe Canadian Myeloma Research Group Database (CMRG-DB) is a prospectively maintained disease-specific database with >7000 patients. The objective of this study was to describe the trends in the treatment landscape and outcomes including early mortality, time to next treatment, and overall survival (OS) in each line of treatment stratified by autologous stem cell transplant (ASCT) receipt among newly-diagnosed MM patients in Canada between 2007 and 2018.ResultsA total of 5154 patients were identified among which 3030 patients (58.8%) received an upfront ASCT and 2124 (41.2%) did not. At diagnosis, the median age was 64 years and 58.6% were males. Bortezomib and lenalidomide were most frequently used (>50%) in first and second-line treatment respectively among both the ASCT and non-ASCT cohort. The median OS was 122.0 months (95% Cl 115.0-135.0 months) and 54.3 months (95% CI 50.8-58.8 months) for the ASCT and non-ASCT cohort respectively with an incremental decrease in OS in each subsequent line of treatment.ConclusionWe present the largest study to date in the Canadian landscape showing the characteristics, therapy usage, and outcomes among MM patients. This information will be critical in benchmarking current outcomes and provide key insight into areas of unmet needs and gaps for improvement of MM patients nationally. 相似文献